This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases. These codons signal the premature end of protein translation, resulting in truncated or non-functional proteins.
The goal is to boost SMN proteinproduction more effectively and offer a more convenient, once-a-year dosing schedule , thereby improving long-term disease management and patient compliance. a leader in RNA-targeted therapeutics. Source link
A new study reveals that C1q can also enter neurons, where it influences proteinproduction, and can accumulate within neurons over time. They also suggest that C1q influences learning, memory, and flexibility in the adult brain, potentially by interacting with specific complexes within neurons that impact proteinproduction.
They found key differences between where mRNAs are made and where the corresponding proteins are being translated in several cell types, suggesting that cells are regulating translation in ways that existing transcriptomic methods, which analyze mRNA production, aren’t able to detect. By Sarah C.P. and Virginia W.
We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.
Structures solved of many different protein classes, including membrane proteins, protein complexes and recently RNA. With capabilities across X-ray Crystallography Crystallisation/co-crystallisation screening of proteins, DNA, and RNA using in-house and commercial screens at various temperature.
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.
Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. “The virus hijacks this protein and makes it do something different than its normal job in cells.
Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors.
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory.
The most compelling evidence for the origin lies in the RNA genome sequence similarities between RaTG13 and SARS-CoV-2 – specifically, a part that encodes the “furin binding site” of the spike protein with which the virus adheres to host cells. Coincidence? I’ve never thought so. b) in an abandoned mine shaft?
Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic proteinproduction in cells and animals.
Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Point-of-care peptide hormone production enabled by cell-free protein synthesis. Ribozyme-mediated RNA synthesis and replication in a model Hadean microenvironment. Szymczak P. Nature Communications.
The market for semaglutide-based products is projected to swell to $71B in less than a decade. All of this future value, of course, relies upon these companies actually making enough of their product to meet the growing demand. In November, Novo Nordisk invested $6B in additional production capacity.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods. coli cells.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods. coli cells.
Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Nature Biotechnology (2009). Nature (2017). & Ueda T.
Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Nature Biotechnology (2009). Nature (2017). & Ueda T.
PELO encodes a protein responsible for restarting ribosomes when they stall on defective mRNA sequences during proteinproduction. The FOCAD and TTC37 proteins are part of and help stabilize an assembly called the superkiller complex, which extracts RNA from stalled ribosomes.
This deadly structure allows it to kill its victims by preventing their cells from making messenger RNA (mRNA) through inhibition of the enzyme RNA Polymerase II. Without mRNA, there is no "message" for our cells' ribosomes to translate into peptides or proteins by linking together amino acids.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content